{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-236516","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2022-09-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.411834+00:00","generated_at":"2026-06-23T17:34:57.339953+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Revolution Medicines promotes Jack Anders to CFO effective Sept 1, 2022","bullets":["Jack Anders, age 45, appointed CFO effective immediately; previously SVP Finance and Principal Financial and Accounting Officer.","Anders joined Revolution Medicines in August 2018; prior roles at Depomed (VP Finance), Elan Pharmaceuticals, Yahoo!, and Novellus Systems.","He began his career at PricewaterhouseCoopers and holds a B.A. in Economics from UCLA; formerly a CPA.","Anders will continue as Principal Financial and Accounting Officer; no departure of prior CFO announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-236516","json":"https://secwatch.observer/filing/0001193125-22-236516.json","markdown":"https://secwatch.observer/filing/0001193125-22-236516.md","text":"https://secwatch.observer/filing/0001193125-22-236516.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522236516/0001193125-22-236516-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522236516/d393123d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T17:34:57.339953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"761abcd289","claim":"Jack Anders changed role as Chief Financial Officer at Revolution Medicines, Inc..","evidence_excerpt":"On September 1, 2022, the Board of Directors (the “Board”) of Revolution Medicines, Inc. (the “Company”) promoted Jack Anders, age 45, to serve as the Chief Financial Officer of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522236516/0001193125-22-236516-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}